glp-1 therapies success rate Weight maintenance after discontinuation of GLP-1 Drugs Market Size to

Learn More A once-weekly, lower-dose dual agonist (GLP-1/GIP) designed for a gentler start and to minimize side effects

It binds to both receptor types, though with different affinities

Exact costs vary based on dosage tier and consultation fees

After approving oral Wegovy in December 2025, the FDA has now also approved Clinical trial data shows that participants taking Foundayo achieved meaningful weight loss compared with placebo, reinforcing its potential as an effective treatment option

This helps catch and fix problems early

What makes GLP-1 drugs particularly intriguing is that they appear to work through a mechanism distinct from traditional addiction treatments